Predix Pharma Closes Series C Round With $43M Total

Predix Pharmaceuticals, a clinical stage drug discovery and development company,
has closed out its Series C round with $43 million. The company said late last
year it had received $15 million in the round. Predix is focused on G-protein
coupled receptor and ion channel drug targets.